Chimeric Antigen Receptor-Engineered Cell Membrane-Coated Nanoparticles Promote Dual-Targeted mRNA-Based Cancer Gene Therapy
- 14 April 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (16) , 15668-15684
Abstract
Gene therapy using mRNA has facilitated progress in cancer therapy. However, its application is hindered by a limited tumor-targeted delivery approach, leading to off-target effects and safety concerns. Chimeric antigen receptor (CAR) molecules enable T cells to recognize specific antigens in a major histocompatibility complex-unrestricted manner. CAR approaches provide an "off-the-shelf" solution for introducing additional targeting functionality to a cell membrane. Cancer cell membrane-coated nanoparticles with homotypic tumor-targeted properties provide a readily accessible platform for gene engineering and membrane extraction. Herein, we demonstrate a CAR-inspired cancer cell membrane-coated platform for delivering an mRNA formulation through a dual tumor-targeted mechanism. The simplified human epidermal growth factor receptor 2 (HER2)-specific CAR molecule (comprising an extracellular HER2-binding domain, a hinge, and a transmembrane domain) was engineered on the cell membrane of cancer cells to establish CAR-CT26 cells. The extracted CAR-CT26 membrane (CARM) was subsequently coated onto the lipid nanoparticle (LNP)-mRNA surface to form a CARM@LNP-mRNA complex. In vitro, the CARM-coated nanoparticles exhibited enhanced mRNA transfection efficiency toward CT26 cells overexpressing target HER2 antigens. Systemic administration of the CARM@LNP-mRNA formulation resulted in stronger tumor-targeting ability and tumor suppression in HER2+ CT26 subcutaneous tumors and peritoneal cavity metastasis models than that observed with the CT26 cell membrane-coated version. Our data suggest that CARM@LNP is a feasible choice for mRNA-based gene therapy. These results provide evidence for the systemic administration of CARM@LNP-mRNA as a promising tumor-targeted therapeutic strategy.Keywords
Funding Information
- Fundo para o Desenvolvimento das Ci?ncias e da Tecnologia (0023/2023/RIB1)
- National Natural Science Foundation of China (82473289)
- Sichuan Science Fund for Distinguished Young Scholars (23NSFJQ0104)
This publication has 41 references indexed in Scilit:
- CAR T Cell Membrane Camouflaged Nanocatalyst Augments CAR T Cell Therapy Efficacy Against Solid TumorSmall, 2024
- Targeted chemotherapy via HER2-based chimeric antigen receptor (CAR) engineered T-cell membrane coated polymeric nanoparticlesBioactive Materials, 2024
- Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapyJournal of Controlled Release, 2022
- In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shiftBiomaterials, 2021
- Targeting Strategies for Tissue-Specific Drug DeliveryCell, 2020
- Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T CellsCancer Cell, 2019
- Engineering biological interactions on the nanoscaleCurrent Opinion in Biotechnology, 2019
- Cancer Cell Membrane‐Coated Upconversion Nanoprobes for Highly Specific Tumor ImagingAdvanced Materials, 2016
- Apoptotic Caspases Prevent the Induction of Type I Interferons by Mitochondrial DNACell, 2014
- Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN ProductionCell, 2014